1. FRI0256 Effects of anifrolumab on oxidative stress and macrophage activation: novel biomarkers and impact of type i interferon blockade in systemic lupus erythematosus. (12th June 2018) Authors: Guo, X.; Wang, S.; Wang, L.; Roskos, L.K.; White, W.I. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0165 Beneficial Effects of An Anti-Ifnar1 Monoclonal Antibody on Immune Cell Dysregulation and Complement System Abnormalities of Systemic Lupus Erythematosus: An Exploratory Analysis of Phase IIB Clinical Trial of Anifrolumab. (15th July 2016) Authors: Guo, X.; Wang, L.; Illei, G.; Brohawn, P.; Higgs, B.W.; White, W.I. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0174 Alteration of mediators of vascular inflammation by anifrolumab in the phase iib muse study in sle. (12th June 2018) Authors: White, W.I.; Seto, N.L.; Playford, M.P.; Casey, K.A.; Smith, M.A.; Carlucci, P.; Yu, B.; Wang, L.; Illei, G.; Mehta, N.; Kaplan, M.J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0238 Suppression of T Cell Activation and Collagen Accumulation by an Anti-Type I Interferon Receptor Monoclonal Antibody in Adult Subjects with Systemic Sclerosis. (10th June 2014) Authors: Guo, X.; Higgs, B.W.; Bay-Jensen, A.-C.; Morehouse, C.; Liu, Z.; Wang, L.; Yoo, S.; Karsdal, M.A.; Yao, Y.; Roskos, L.K.; White, W.I. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0244 Sustained Suppression of Rheumatoid Arthritis Disease Markers by Mavrilimumab but Not Golimumab in Anti-Tumor Necrosis Factor-Inadequate Responders: An Exploratory Analysis in The Phase IIB Earth Explorer 2 Clinical Trial. (15th July 2016) Authors: Guo, X.; Wang, S.; Bay-Jensen, A.C.; Karsdal, M.A.; Godwood, A.; Close, D.; Ryan, P.C.; Roskos, L.K.; White, W.I. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0212 Sustained Response to Mavrilimumab in Rheumatoid Arthritis Patients VIA Suppression of Macrophage and T Cells. (9th June 2015) Authors: Guo, X.; Sinibaldi, D.; Kuziora, M.; Brohawn, P.; Ryan, P.C.; Bay-Jensen, A.C.; Karsdal, M.A.; Roskos, L.K.; White, W.I. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 734 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗